Outcomes of melanoma in recipients of solid organ transplant

Dapprich, Daniel C.; Weenig, Roger H.; Rohlinger, Audrey L.; Weaver, Amy L.; Quan, Katherine K. Lim; Keeling, James H.; Walsh, John; Otley, Clark C.; Christenson, Leslie J.

doi:10.1016/j.jaad.2008.05.015

“…Some data report up to an eightfold increase of this tumor [34], but other studies did not observe an increased incidence [35]. Recently, a study reported similar outcomes of melanoma in SOTRs compared with prognostically matched nonimmunosuppressed patients [36] for melanoma <2 mm Breslow thickness, but a worse outcome for melanoma >2 mm Breslow thickness in these patients compared with the general population [37,38]. Owing to the limited number of reports concerning this tumor, the authors recommend that SOTRs patients with a history of melanoma or those who are at high risk for developing melanoma must be monitored closely, with dermatological consultations every 3 months.…”

Section: Melanomamentioning

confidence: 99%

Skin care in solid organ transplant recipients: risk-adjusted follow-up

Shafaeddin-Schreve

¹

,

Anliker

²

,

Arnold

³

et al. 2012

Expert Review of Dermatology

1

0

View full text Add to dashboard Cite

“…43 Recent studies of organ transplant despite a history of melanoma have not found an increased risk of worse outcomes in these cases. 5,6,45 In essence, although melanoma is a serious malignancy, these studies raise the question of whether melanoma should be an exclusion criterion for a lifesaving organ transplant. To date, no conclusive evidence suggests that patients who have a diagnosis of melanoma would fare worse after receiving an organ transplant.…”

Section: Article Highlightsmentioning

confidence: 99%

“…47 The latter have been shown to have a tumorigenic effect through interference with DNA repair mechanisms. 45 . Regardless, the addition of cyclosporine, a commonly used calcineurin inhibitor, to previous regimens of azathioprine and prednisone for OTRs creates an increased risk of cutaneous cancers.…”

Section: Clinical Course Of Melanoma In Lymphoma Patientsmentioning

confidence: 99%

Melanoma in Immunosuppressed Patients

Kubica

¹

,

Brewer

²

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The immunogenic characteristics of malignant melanoma are intriguing. To date, multiple studies exist regarding the immunogenicity of melanoma. In this article, we summarize data in the literature on the role of immunosuppression in melanoma and discuss several immunocompromised patient populations in detail. A comprehensive PubMed search was conducted with no date limitation. The following search terms were used: melanoma in combination with immunosuppression, immunocompromised, genetics, antigen processing, UV radiation, organ transplantation, organ transplant recipients, lymphoproliferative disease, lymphoma, CLL, NHL, radiation, and HIV/AIDS. Although no formal criteria were used for inclusion of studies, most pertinent studies on the topic were reviewed, with the exception of smaller case reports and case series. The included studies were generally large (Ն1000 patients in organ transplant recipient studies; Ն500 patients in lymphoma studies), with a focus on institutional experiences, or population-based national or international epidemiologic studies. Melanoma-induced immunosuppression, the role of UV radiation in melanoma development, and the epidemiology, clinical course, and prognosis of melanoma in immunocompromised patients are highlighted. Organ transplant recipients, patients with lymphoproliferative disorders, patients with iatrogenic immunosuppression, and patients with human immunodeficiency virus infection/AIDS are also highlighted. Recommendations are proposed for the care and monitoring of immunosuppressed patients with melanoma. With better understanding of the molecular microenvironment and clinical course of melanoma in immunosuppressed patients, novel therapies could be developed and outcomes potentially affected in these patients.

show abstract

“…47 The latter have been shown to have a tumorigenic effect through interference with DNA repair mechanisms. 45 These medications may promote tumor progression and increase invasiveness (Geissler and Schlitt . Regardless, the addition of cyclosporine, a commonly used calcineurin inhibitor, to previous regimens of azathioprine and prednisone for OTRs creates an increased risk of cutaneous cancers.…”

Section: Melanoma and Iatrogenic Immunosuppressionmentioning

confidence: 99%

Melanoma in immunosuppressed patients

Brewer

¹

2010

Expert Review of Dermatology

View full text Add to dashboard Cite

The immunogenic characteristics of malignant melanoma are intriguing. To date, multiple studies exist regarding the immunogenicity of melanoma. In this article, we summarize data in the literature on the role of immunosuppression in melanoma and discuss several immunocompromised patient populations in detail. A comprehensive PubMed search was conducted with no date limitation. The following search terms were used: melanoma in combination with immunosuppression, immunocompromised, genetics, antigen processing, UV radiation, organ transplantation, organ transplant recipients, lymphoproliferative disease, lymphoma, CLL, NHL, radiation, and HIV/AIDS. Although no formal criteria were used for inclusion of studies, most pertinent studies on the topic were reviewed, with the exception of smaller case reports and case series. The included studies were generally large (Ն1000 patients in organ transplant recipient studies; Ն500 patients in lymphoma studies), with a focus on institutional experiences, or population-based national or international epidemiologic studies. Melanoma-induced immunosuppression, the role of UV radiation in melanoma development, and the epidemiology, clinical course, and prognosis of melanoma in immunocompromised patients are highlighted. Organ transplant recipients, patients with lymphoproliferative disorders, patients with iatrogenic immunosuppression, and patients with human immunodeficiency virus infection/AIDS are also highlighted. Recommendations are proposed for the care and monitoring of immunosuppressed patients with melanoma. With better understanding of the molecular microenvironment and clinical course of melanoma in immunosuppressed patients, novel therapies could be developed and outcomes potentially affected in these patients.

show abstract

Outcomes of melanoma in recipients of solid organ transplant

Cited by 52 publications

References 36 publications

Skin care in solid organ transplant recipients: risk-adjusted follow-up

Skin care in solid organ transplant recipients: risk-adjusted follow-up

Melanoma in Immunosuppressed Patients

Melanoma in immunosuppressed patients

Contact Info

Product

Resources

About